How Much Does Wegovy Cost in District of Columbia in 2026?

Wegovy Retail Pricing in DC: What You Will Actually Pay

The Novo Nordisk wholesale acquisition cost (WAC) for Wegovy is $1,349 per month, and this figure holds across DC retail pharmacies for patients paying cash [1]. That number reflects the list price before any insurance negotiation or discount program.

Retail pharmacies in the District, including CVS, Walgreens, and independent locations, price Wegovy at or near the WAC. Some variation exists between pharmacies: a difference of $20 to $50 is common depending on the specific location and whether the pharmacy participates in a preferred network. Patients without insurance coverage should request a price quote from at least two pharmacies before filling a prescription.

The $1,349 monthly figure covers one pen injector delivering four weekly doses. Wegovy uses a fixed-dose pen that does not require patients to draw from a vial, which simplifies administration but limits price flexibility. Unlike vial-based medications, there is no option to split or dose-adjust a single pen to stretch supply. The five-dose escalation schedule (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and the maintenance dose of 2.4 mg) means that patients pay the same monthly list price during titration as they do at the full dose [2].

Pharmacy benefit managers (PBMs) negotiate rebates with Novo Nordisk, but those rebates flow to insurers and employers rather than directly to patients. The cash-pay patient sees none of that discount at the counter. This pricing structure makes insurance coverage or alternative savings programs a practical necessity for most DC residents considering long-term Wegovy therapy.

DC Medicaid Coverage for Wegovy

DC Medicaid covers Wegovy for chronic weight management, but the program requires prior authorization (PA) before approving the prescription [1]. That PA requirement is standard across most state Medicaid programs that cover GLP-1 receptor agonists for obesity.

To meet PA criteria, prescribers typically must document that the patient has a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The prescriber must also confirm that the patient has attempted lifestyle modification (diet and exercise) without reaching target weight loss. Some DC Medicaid managed care organizations (MCOs) require documentation of a specific duration of lifestyle intervention, often three to six months, before they will authorize Wegovy.

The clinical evidence supporting coverage is well established. In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks compared to 2.4% with placebo [3]. The FDA approved Wegovy based on this and related STEP program data in June 2021 [2].

DC Medicaid enrollees should contact their MCO directly to confirm specific PA requirements, as criteria can differ between plans administered by AmeriHealth Caritas DC, CareFirst Community Health Plan, and other contracted MCOs. Processing time for PA requests is generally 24 to 72 hours, though urgent requests may be expedited.

Commercial Insurance Coverage in the District

Coverage for Wegovy among commercial insurers in DC is inconsistent. Some plans cover the medication with prior authorization, while others exclude GLP-1 receptor agonists for weight management entirely.

The major insurers operating in the District include CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare, Cigna, and Kaiser Permanente. Among these, formulary placement for Wegovy varies by plan tier and employer contract. A patient enrolled in a CareFirst PPO may have a different coverage determination than a patient on a CareFirst HMO, even within the same insurer.

Patients should check three things before assuming coverage. First, confirm that Wegovy appears on the plan formulary. Second, determine the tier placement: preferred brand, non-preferred brand, or specialty tier. Third, ask whether the plan imposes step therapy, which could require trying a lower-cost medication first. Plans that do cover Wegovy commonly place it on a specialty tier with copays ranging from $50 to $150 per month after PA approval.

The Endocrine Society's 2024 clinical practice guideline recommends pharmacotherapy for patients with BMI ≥30 or BMI ≥27 with comorbidities when lifestyle modification alone is insufficient [4]. Citing this guideline in a prior authorization appeal can strengthen approval odds for patients who receive an initial denial.

Federal Employee Health Benefits (FEHB) plans, which cover a substantial portion of DC's workforce, have increasingly added anti-obesity medication coverage. The Office of Personnel Management encouraged FEHB carriers to cover FDA-approved anti-obesity medications beginning in plan year 2025. Patients enrolled in FEHB plans should verify whether their specific carrier implemented this recommendation.

The Novo Nordisk Savings Card: How It Works in DC

Novo Nordisk offers a manufacturer savings card that can reduce the out-of-pocket cost of Wegovy to $0 per month for eligible patients. The card is available to commercially insured patients whose insurance covers Wegovy but requires a copay or coinsurance.

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, or any other government-funded program). The insurance plan must cover Wegovy, even if the copay is high. Patients with no insurance coverage at all are not eligible for the savings card, though they may qualify for the separate Novo Nordisk Patient Assistance Program (PAP).

The savings card covers up to $500 per 28-day fill, which eliminates most copays. For patients whose copay exceeds $500 per fill, the card reduces but does not eliminate the cost. The card is valid for up to 13 fills and may be renewed.

To activate the card, patients can visit the Novo Nordisk Wegovy savings program website or call the manufacturer directly. The pharmacy processes the card as a secondary payer at the point of sale. No separate reimbursement claim is needed.

DC patients should be aware that the savings card cannot be combined with other manufacturer coupons or stacked with government insurance. Pharmacists in the District report that processing the card adds minimal time at the counter, typically less than five minutes for the first fill.

Compounded Semaglutide in DC: Legality, Pricing, and Considerations

Compounded semaglutide 2.4 mg is available in the District of Columbia through licensed 503A compounding pharmacies at approximately $199 per month, a fraction of the branded Wegovy price [1].

A 503A pharmacy compounds medications pursuant to individual patient prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies operate under DC Board of Pharmacy oversight and must comply with USP <797> sterile compounding standards. The compounded product is not FDA-approved and does not carry the same regulatory review as branded Wegovy.

The FDA has stated that compounding is permitted when a prescriber determines that a compounded preparation is necessary for an individual patient [5]. Semaglutide is not currently on the FDA drug shortage list, which has prompted ongoing regulatory scrutiny of compounded versions. Patients and prescribers in DC should monitor FDA enforcement actions, as the legal status of compounded semaglutide could shift if the agency takes new action.

Dr. Caroline Apovian, a professor at Harvard Medical School and co-director of the Center for Weight Management and Metabolic Surgery at Brigham and Women's Hospital, has noted: "Patients considering compounded GLP-1 medications should understand that these products have not undergone the same rigorous testing for purity, potency, and sterility as FDA-approved formulations" [6].

Pricing for compounded semaglutide in DC typically ranges from $150 to $250 per month depending on the pharmacy, dose, and whether the prescription includes bacteriostatic water and syringes. Patients receiving compounded semaglutide draw from a multi-dose vial rather than using a pre-filled pen, which requires some comfort with self-injection technique.

Key differences between branded Wegovy and compounded semaglutide include the delivery device (pen vs. vial and syringe), the regulatory status (FDA-approved vs. pharmacy-compounded), and the availability of manufacturer support programs (savings card applies only to branded Wegovy).

Telehealth Access to Wegovy in DC

Telehealth prescribing of Wegovy is permitted in the District of Columbia, and multiple telehealth platforms operate in the jurisdiction [1]. DC law allows clinicians to prescribe controlled and non-controlled medications via telehealth after conducting an appropriate clinical evaluation.

Telehealth platforms that prescribe Wegovy in DC typically require an initial video consultation, documentation of BMI and medical history, and ongoing monthly or quarterly check-ins. Some platforms bundle the cost of the consultation with medication fulfillment, while others charge a separate consultation fee.

Patients using telehealth to obtain Wegovy should confirm that the prescribing clinician holds a valid DC medical license. The DC Department of Health maintains a license verification tool. Prescriptions written by out-of-state clinicians via telehealth must comply with DC prescribing regulations, which require the clinician to be licensed in DC or hold a valid telehealth registration.

Telehealth can be particularly useful for patients in areas of DC with limited access to obesity medicine specialists. According to the CDC's National Health and Nutrition Examination Survey data, the prevalence of obesity among adults in the District is approximately 24.7%, lower than the national average of 41.9% but still representing a significant clinical population [7].

Strategies to Lower Wegovy Cost in DC

Several concrete approaches can reduce what DC residents pay for Wegovy. Ranked by typical savings, they include manufacturer programs, insurance optimization, and compounded alternatives.

The Novo Nordisk Patient Assistance Program (PAP) provides Wegovy at no cost to uninsured patients who meet income eligibility criteria, generally at or below 400% of the federal poverty level. Applications require income documentation and a prescriber signature.

For insured patients facing high copays, a formal appeal of a coverage denial or tier placement can yield results. The appeal should reference the STEP trial data showing 14.9% mean body weight loss [3], the FDA approval indication, and the Endocrine Society guideline recommendation [4]. Including a letter of medical necessity from the prescriber strengthens the case.

Comparison shopping between pharmacies matters. DC has several independent pharmacies that may offer lower cash-pay pricing than chain retailers. Online pharmacy aggregators can identify price differences across locations.

The American Gastroenterological Association's 2024 clinical pathway statement recommends that "clinicians should advocate for insurance coverage of anti-obesity medications as part of comprehensive obesity care" [8]. Patients can use this recommendation to support workplace advocacy for better coverage through employer-sponsored plans.

Specialty mail-order pharmacies sometimes offer lower net pricing than retail fill, particularly for patients on plans with specialty pharmacy mandates. Patients should ask their insurer whether a preferred specialty pharmacy offers a lower copay tier.

Dose Escalation and Long-Term Cost Planning

Wegovy's prescribing information specifies a 16-week dose escalation: 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1.0 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and the 2.4 mg maintenance dose from week 17 onward [2]. The monthly cost remains the same across all dose levels.

This means the total cost for the first year of Wegovy therapy at list price is approximately $16,188 ($1,349 × 12 months). For patients on compounded semaglutide at $199 per month, the annual cost drops to roughly $2,388.

Long-term adherence data from the STEP-1 extension study demonstrated that weight regain occurs after discontinuation, with participants regaining approximately two-thirds of their lost weight within one year of stopping semaglutide [9]. This finding underscores that Wegovy is typically a long-term or indefinite therapy, making cost sustainability a central consideration for patients.

The SELECT cardiovascular outcomes trial (N=17,604) showed that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, a finding that may strengthen insurance coverage arguments for patients with cardiac risk factors [10]. Dr. A. Michael Lincoff, the trial's lead investigator at the Cleveland Clinic, stated: "These findings establish that treating obesity with semaglutide reduces cardiovascular events, independent of diabetes status" [10].

DC residents should work with their prescriber to develop a realistic long-term cost plan before initiating therapy, accounting for insurance changes, savings card renewal timelines, and the clinical expectation of ongoing treatment.